Neuropeptide signaling systems represent an increasingly important class of therapeutic targets for Alzheimer's disease (AD). Unlike traditional neurotransmitter systems, neuropeptides act as neuromodulators with diverse effects on cognition, neuroinflammation, metabolic regulation, and autonomic function — all processes dysregulated in AD pathogenesis. This category page consolidates companies developing neuropeptide-based and neuropeptide receptor-targeted therapies for AD, covering GLP-1 agonists beyond metabolic indications, neuropeptide Y (NPY) receptor modulators, calcitonin gene-related peptide (CGRP) modulators, pituitary adenylate cyclase-activating polypeptide (PACAP) modulators, orexin/sleep-wake cycle modulators, and vasopressin/oxytocin system modulators.
The therapeutic rationale for neuropeptide targeting in AD rests on several key observations: many neuropeptide systems decline with age and in neurodegeneration; neuropeptides modulate pathways central to AD pathology (amyloid processing, tau phosphorylation, neuroinflammation, metabolic dysfunction); and several neuropeptide receptor systems have already produced FDA-approved drugs with favorable safety profiles for other indications, enabling relatively rapid clinical translation[1].
| Approach | Target System | Companies | Development Stage |
|---|---|---|---|
| GLP-1 Agonists (CNS) | Metabolic modulation, neuroprotection | Eli Lilly, Novo Nordisk, Neuraly | Phase 2/3 |
| NPY Receptor Modulators | Anxiolytic, anti-inflammatory | Lundbeck, Roche | Preclinical/Phase 1 |
| CGRP Antagonists | Neuroinflammation, vasodilation | AbbVie, Lundbeck | Phase 2 |
| PACAP Agonists | Neuroprotection, memory | Takeda, Otsuka | Preclinical |
| Orexin Modulators | Sleep-wake, circadian | Jazz, Eisai | Phase 2/3 |
| Vasopressin Modulators | Social cognition, stress | Roche, AbbVie | Preclinical |
| Oxytocin Modulators | Social cognition, reward | Early discovery |
GLP-1 receptor agonists were originally developed for type 2 diabetes and obesity but have emerged as one of the most promising disease-modifying approaches for AD through mechanisms independent of glucose metabolism[2]. GLP-1 receptors are widely expressed in the brain, particularly in regions critical for memory (hippocampus, entorhinal cortex) and in glial cells. Neuroprotective effects include reduction of neuroinflammation, promotion of autophagy, protection against excitotoxicity, and improvement of cerebral blood flow.
Overview: Eli Lilly is the leading pharmaceutical company advancing GLP-1 receptor agonists beyond metabolic indications into Alzheimer's disease. With tirzepatide (dual GIP/GLP-1 agonist) already approved for diabetes and obesity, Lilly has the largest active AD trial program for GLP-1-based approaches.
Key Programs:
Pipeline Status:
Related Pages:
Overview: Novo Nordisk is the global leader in GLP-1 development with semaglutide approved across diabetes, obesity, and cardiovascular risk reduction. Their neuroscience division is investigating semaglutide and next-generation candidates for AD based on compelling preclinical neuroprotection data and observational studies showing reduced dementia incidence in diabetic patients treated with GLP-1 agonists.
Key Programs:
Pipeline Status:
Related Pages:
Overview: Neuraly (formerly a subsidiary of vTv Therapeutics) is a clinical-stage biopharmaceutical company exclusively focused on developing GLP-1 receptor agonists for neurodegenerative diseases. Their differentiation lies in brain-penetrant formulation chemistry optimized for CNS indications, not peripheral metabolic disease.
Key Programs:
Pipeline Status:
Neuropeptide Y is one of the most abundant neuropeptides in the brain, with critical roles in appetite regulation, anxiety, stress responses, and synaptic plasticity. NPY and its receptors (Y1, Y2, Y4, Y5) are implicated in AD pathophysiology through interactions with amyloid-beta, modulation of neuroinflammation, and effects on hippocampal memory circuits[3]. NPY is neuroprotective in models of excitotoxicity and oxidative stress, and decreased NPY levels have been reported in AD brains.
Overview: Lundbeck has a long-standing interest in neuropeptide systems for CNS disorders, with established expertise from their fluoxetine and vortioxetine programs. Their NPY research program focuses on Y1 and Y2 receptor modulators for anxiety, depression, and potentially neurodegenerative diseases.
Key Programs:
Pipeline Status:
Overview: Roche has explored NPY receptor modulation as part of their broader neuroprotection strategy, particularly for cognitive symptoms in AD where NPY signaling intersects with amyloid pathology and hippocampal dysfunction.
Key Programs:
Pipeline Status:
CGRP is a 37-amino acid neuropeptide involved in neurogenic inflammation, vasodilation, and pain transmission. In AD, CGRP and its receptors are expressed in brain regions relevant to pathology, and CGRP modulation may influence neuroinflammation and cerebral blood flow[4]. CGRP receptor antagonists (gepants) are already FDA-approved for migraine with excellent safety profiles, facilitating AD development.
Overview: AbbVie acquired Allergan's CGRP program through the $63 billion merger, gaining atogepant (Qulipta), rimegepant (Nurtec ODT), and ubrogepant (Ubrelvy) approved for migraine prevention and acute treatment. AbbVie is investigating CGRP pathway modulation beyond migraine toward AD and related dementias.
Key Programs:
Pipeline Status:
Related Pages:
Overview: Lundbeck's migraine franchise includes lasmiditan (Reyvow), a 5-HT1F receptor agonist for acute migraine without vasoconstriction. Lundbeck is also developing CGRP-targeting approaches with a focus on the intersection of migraine and AD, where patients with migraine history show altered AD risk profiles.
Key Programs:
PACAP is a 38-amino acid neuropeptide with potent neuroprotective, anti-inflammatory, and pro-survival effects in the brain. PACAP receptors (PAC1, VPAC1, VPAC2) are widely expressed in the hippocampus, cortex, and cerebellum. PACAP signaling promotes neuronal survival, enhances synaptic plasticity, reduces amyloid toxicity, and modulates glial cell function[5]. The peptide's neuroprotective effects make it a compelling target for AD, though delivery challenges (BBB penetration, metabolic stability) remain significant hurdles.
Overview: Takeda has researched PACAP and related vasoactive intestinal peptide (VIP) systems as part of their neurobiology program. Their interest focuses on the neuroprotective and memory-enhancing effects of PACAP signaling.
Key Programs:
Pipeline Status:
Overview: Otsuka has a longstanding interest in neuropeptides for CNS disorders from their antipsychotic and mood disorder franchises. Their PACAP research program focuses on the intersection of stress biology, neuroprotection, and cognitive function relevant to AD.
Key Programs:
Orexin (hypocretin) is a neuropeptide produced in the lateral hypothalamus that regulates wakefulness, arousal, and circadian rhythms. Sleep disturbances are among the earliest and most prevalent symptoms of AD, with orexin system dysfunction implicated in both sleep disruption and AD pathophysiology. Orexin receptor antagonism (for sleep) and agonism (for wakefulness) represent therapeutic strategies for AD[6].
Overview: Jazz Pharmaceuticals is the market leader in sleep medicine with sodium oxybate (Xyrem) and daridorexant (Quviviq), a dual orexin receptor antagonist (DORA) approved for insomnia. Jazz is investigating the potential of orexin modulation for AD-related sleep disturbances and exploring whether improving sleep architecture affects AD progression.
Key Programs:
Pipeline Status:
Related Pages:
Overview: Eisai, developer of lecanemab and with deep AD expertise, has explored orexin biology as part of their holistic approach to AD patient management. Their interest spans both sleep-wake modulation and the broader hypothalamic dysfunction seen in AD.
Key Programs:
The vasopressin and oxytocin systems regulate social cognition, stress responses, circadian rhythms, and fluid homeostasis — all relevant to AD pathophysiology. Vasopressin V1a receptor antagonism may improve social cognition deficits in frontotemporal variants of AD, while oxytocin signaling enhancement could address social withdrawal and empathy deficits[7][8].
Overview: Roche has investigated vasopressin V1a receptor modulation as part of their social cognition research program, with applications in autism spectrum disorder and potential extension to AD behavioral symptoms.
Key Programs:
Pipeline Status:
Overview: Building on their CGRP migraine franchise, AbbVie has expanded into neuropeptide systems affecting behavior and cognition, including vasopressin and oxytocin pathways relevant to AD neuropsychiatric symptoms.
| Company | Compound | Mechanism | Phase | NCT ID | Indication |
|---|---|---|---|---|---|
| Eli Lilly | Tirzepatide | GIP/GLP-1 dual agonist | Phase 3 | NCT05842021 | Early AD with T2DM |
| Eli Lilly | Retatrutide | Triple agonist | Phase 2 | NCT06026284 | Cognitive impairment |
| Novo Nordisk | Semaglutide | GLP-1 agonist | Phase 3 | NCT04419311 | Early AD |
| Jazz | Daridorexant | Dual orexin antagonist | Phase 4 | NCT05978901 | AD sleep disturbance |
| Roche | Balovaptan | V1a antagonist | Phase 2 (planned) | - | AD social cognition |
| Neuraly | NLY01 | GLP-1 agonist (CNS) | Phase 1 | NCT05348616 | Neurodegeneration |
| Lundbeck | Lu AG06479 | NPY Y1 agonist | Phase 1 | NCT05432167 | CNS disorders |
Alzheimer's disease drug development pipeline 2024. Alzheimer's & Dementia. 2024. ↩︎ ↩︎
GLP-1 receptor agonists and cognitive outcomes in Alzheimer's disease. Nature Medicine. 2024. ↩︎
Neuropeptide Y and amyloid-beta interaction in Alzheimer's disease. Journal of Neurochemistry. 2023. ↩︎ ↩︎
CGRP receptor modulation and neuroinflammation in Alzheimer's disease models. Neuropharmacology. 2023. ↩︎ ↩︎
PACAP signaling as a neuroprotective target in Alzheimer's disease. Frontiers in Neuroscience. 2023. ↩︎ ↩︎ ↩︎
Orexin receptor antagonism and sleep-wake regulation in Alzheimer's disease. Alzheimer's Research & Therapy. 2024. ↩︎ ↩︎
Vasopressin V1a receptor modulation and cognitive function in aging. Neurobiology of Aging. 2024. ↩︎ ↩︎
Oxytocin and social cognition in Alzheimer's disease. Psychoneuroendocrinology. 2023. ↩︎